Merck KGaA presses on with 250 million euros investment in Chinese production facilities

4 November 2016

German pharma major Merck KGaA (MRK: DE) has inaugurated its 170 million euros ($189 million) Nantong pharmaceutical plant in China at the same time as announcing a further 80 million euros investment in a life sciences center nearby.

Merck KGaA is the first multinational company to dedicate a green-field investment to the production of pharmaceuticals on China’s Essential Drug List, something which goes on at the Nantong plant, while the life science center will manufacture high-purity inorganic salts, cell culture media products as well as ready-to-use media.

"China is of strategic importance to Merck KGaA as a key driver of our sustainable growth"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK